Evaluation of miglustat as maintenance therapy after enzyme therapy in adults with stable type 1 Gaucher disease: a prospective, open-label non-inferiority study

Table 2 Baseline and change from baseline in liver volume during up to 24 months of miglustat therapy (primary analysis)

	Non-splenectomized	Splenectomized	All
	(N = 23)	(N = 9)	(N = 32)
Baseline absolute value (mL)
Mean ± SD	1742 ± 440	1857 ± 604	1775 ± 484
End of treatment absolute value (mL)
Mean ± SD	1736 ± 353	1704 ± 470	1727 ± 382
Absolute change from baseline (mL)
Mean	−6.4	−152.6	−47.5
95% CI	(−124, 111)	(−395, 90)	(−151, 56)
Percent change from baseline
Mean	1.3	−7.2	−1.1
95% CI	(−4.6%, 7.3%)	(−16.6%, 2.2%)	(−6.0%, 3.9%)

ISSN: 1750-1172